Generated by AI
Aspire Biopharma Holdings, Inc. is a biopharmaceutical company focused on developing and marketing sublingual delivery technologies for drugs, nutraceuticals, and supplements. Its platform is designed to improve how active ingredients are absorbed by bypassing the gastrointestinal tract, with applications centered on faster onset and more precise administration. The company’s current portfolio includes soluble and fast-acting formulations, such as aspirin-based products for cardiology emergencies and pain management, along with other development programs spanning wellness and specialty therapeutic categories. Aspire Biopharma Holdings, Inc. operates at the intersection of pharmaceuticals and drug-delivery innovation, serving markets that value rapid absorption, dosage control, and alternative delivery formats for established compounds.
Website23150 Fashion Drive
Estero, FL, 33928
United States
The latest articles about ASBP.
Detailed price information for Aspire Biopharma Holdings Inc (ASBP-Q) from The Globe and Mail including charting and trades.
Brings total authorized repurchase to $10 millionReflects leadership's view that Aspire-Lakewood's share price does not reflect the Company's financial strength or long-term growth opportunityIncreased authorization supported by strength of newly acquired Dura Control Systems Corp's (DCSC) full year 2025 and six months ended June 30, 2026 revenue of approximately $209.5 million and Adjusted EBITDA1 of $22.
Detailed price information for Aspire Biopharma Holdings Inc (ASBP-Q) from The Globe and Mail including charting and trades.
Summary of Sep 9's posts. Generated by AI.
Summary of Jun 12's posts. Generated by AI.
Summary of Aug 11's posts. Generated by AI.
Investors talking about ASBP also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.